Top

Published in:

01-04-2012 | Clinical Trial

Triple-negative breast cancer: the impact of guideline-adherent adjuvant treatment on survival—a retrospective multi-centre cohort study

Authors: L. Schwentner, R. Wolters, K. Koretz, M. B. Wischnewsky, R. Kreienberg, R. Rottscholl, A. Wöckel

Published in: Breast Cancer Research and Treatment | Issue 3/2012

Abstract

Triple-negative breast cancer (TNBC) (ER−/PGR−/erb-2−) constitutes an aggressive subtype in breast cancer because it is accompanied by a significant decrease in overall survival (OAS) and recurrence-free survival (RFS) compared with hormone receptor positive breast cancers. This retrospective cohort study investigates the following issues: (1) Is there an impact of guideline-adherent treatment on RFS and OAS in TNBC? (2) Which adjuvant treatment has the most important impact on RFS and OAS in TNBC? This German retrospective multi-centre cohort study included 3,658 patients with primary breast cancer recruited from 2000 to 2005. The definition of guideline adherence was based on the German national S3 guideline for diagnosis and treatment of breast cancer (2004). A total of 371 patients (10.1%) had TNBC. Compared with HR+/erb-2− breast cancer (P = 0.001; HR = 1.75; 95% CI: 1.27–2.40), the recurrence rate of TNBC was significantly higher (P < 0.001; HR = 2.86; 95% CI: 2.17–3.76). Furthermore, the 5-year RFS and OAS was significantly lower in TNBC (RFS: 74.8% [95% CI: 68.8–80.8%] vs. 86.5% [95% CI: 84.6–88.4%] [log-rank P = 0.0001]) (OAS: 75.8% [95% CI: 69.9–81.8%] vs. 86.0% [95% CI: 84.1–87.9%] [log-rank P = 0.0001]). The most important parameters predicting RFS and OAS in TNBC after receiving guideline-conform chemotherapy are guideline-adherent surgery, radiotherapy, nodal status and grading. Overall, 66.8% TNBC were found with one or more (18%) guideline violations, which subsequently impaired OAS and RFS. The most important impact on OAS and RFS in TNBC patients was because of guideline violations (GV) concerning adjuvant radiotherapy and GV concerning adjuvant chemotherapy. Patients with TNBC primarily have a worse prognosis in terms of RFS and OAS than patients of a primarily non-TNBC phenotype. There is a strong association between guideline-adherent adjuvant treatment and improved survival outcome in TNBC. The outcome significantly decreases with the number of guideline violations.

Badve S, Dabbs DJ, Schnitt SJ, Baehner FL, Decker T, Eusebi V, Fox SB, Ichihara S, Jacquemier J, Lakhani SR et al (2011) Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol 24(2):157–167PubMedCrossRef

Rakha EA, Ellis IO (2009) Triple-negative/basal-like breast cancer: review. Pathology 41(1):40–47PubMedCrossRef

Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO (2007) Prognostic markers in triple-negative breast cancer. Cancer 109(1):25–32PubMedCrossRef

Hudis CA, Gianni L (2011) Triple-negative breast cancer: an unmet medical need. Oncologist 16(1):1–11PubMedCrossRef

Teng YH, Thike AA, Wong NS, Tan PH (2011) Therapeutic targets in triple negative breast cancer: where are we now? Recent Pat Anticancer Drug Discov 6(2):196–209PubMedCrossRef

Pal SK, Childs BH, Pegram M (2011) Triple negative breast cancer: unmet medical needs. Breast Cancer Res Treat 125(3):627–636PubMedCrossRef

Remmele W, Stegner HE (1987) Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8(3):138–140PubMed

Wolters R, Regierer AC, Schwentner L, Geyer V, Possinger K, Kreienberg R, Wischnewsky MB, Wöckel A (2011) A comparison of international breast cancer guidelines: do the national guidelines differ in treatment recommendations? Eur J Cancer doi:10.1016/j.ejca.2011.06.020

Kreienberg R, Kopp I, Lorenz W, Budach W, Dunst J, Lebeau A et al. (2004) Guidelines for diagnosis and treatment for breast cancer in women. National Cancer Society 2004

10.

Foulkes WD, Smith IE, Reis-Filho JS (2010) Triple negative breast cancer. N Engl J Med 363(20):1938–1948PubMedCrossRef

11.

Chacon RD, Costanzo MV (2010) Triple negative breast cancer. Breast Cancer Res 12(2):S3PubMed

12.

Carey L, Winer E, Viale G, Cameron D, Gianni L (2010) Triple negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol 7(12):683–692PubMedCrossRef

13.

Schwamm LH, Fonarow GC, Reeves MJ, Pan W, Frankel MR, Smith EE et al (2008) Get with guidelines: stroke is associated with sustained improvement in care for patients hospitalized with acute stroke or transient ischemic attack. Circulation 119(1):107–115PubMedCrossRef

14.

Wöckel A, Kurzeder C, Geyer V, Novopashenny I, Wolters R, Wischnewsky M et al (2010) Effects of guideline adherence in primary breast cancer: a 5 year multi-center cohort study of 3976 patients. Breast 19:120–127PubMedCrossRef

15.

Hamaker ME, Schreurs WH, Uppelschoten JM, Smorenburg CH (2009) Breast cancer in the elderly: retrospective study on diagnosis and treatment according to national guidelines. Breast J 15:26–33PubMedCrossRef

16.

Varga D, Wischnewsky M, Atassi Z, Wolters R, Geyer V, Strunz K, Kreienberg R, Woeckel A (2010) Does guideline-adherent therapy improve the outcome for early-onset breast cancer patients? Oncology 78(3–4):189–195PubMedCrossRef

17.

Hancke K, Denkinger MD, König J, Kurzeder C, Wöckel A, Herr D, Blettner M, Kreienberg R (2010) Standard treatment of female patients with breast cancer decreases substantially for women aged 70 years and older: a German clinical cohort study. Ann Oncol 21(4):748–753PubMedCrossRef

18.

Hebert-Croteau N, Brisson J, Latreille J, Rivard M, Abdelaziz N, Martin G (2004) Compliance with consensus recommendations for systemic therapy is associated with improved survival of women with nodal negative breast cancer. J Clinical Oncol 22:3685–3693CrossRef

Title: Triple-negative breast cancer: the impact of guideline-adherent adjuvant treatment on survival—a retrospective multi-centre cohort study
Authors: L. Schwentner
R. Wolters
K. Koretz
M. B. Wischnewsky
R. Kreienberg
R. Rottscholl
A. Wöckel
Publication date: 01-04-2012
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 3/2012
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-011-1935-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2012

CD24 Ala57Val polymorphism predicts pathologic complete response to sequential anthracycline- and taxane-based neoadjuvant chemotherapy for primary breast cancer

MDM2 SNP309 and TP53 R72P associated with severe and febrile neutropenia in breast cancer patients treated with 5-FU/epirubicin/cyclophosphamide

Biopsy sampling of breast lesions: comparison of core needle- and vacuum-assisted breast biopsies

Pathological complete response rates following different neoadjuvant chemotherapy regimens for operable breast cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II)

The KL-VS sequence variant of Klotho and cancer risk in BRCA1 and BRCA2 mutation carriers

Characterization of BRCA1 and BRCA2 splicing variants: a collaborative report by ENIGMA consortium members

Keynote webinar | Spotlight on antibody–drug conjugates in cancer